- One of the challenges in cartilage repair is that some procedures can provide meaningful short-term pain relief without restoring durable, functional cartilage capable of withstanding the demands of an active joint.
- Regentis Biomaterials is taking a regenerative approach with GelrinC, a cell-free, off-the-shelf hydrogel designed to temporarily fill cartilage defects while guiding the healthy surrounding tissue to regenerate new, natural and highest hyalin quality cartilage.
- Recent long-term MRI and peer-reviewed clinical data have provided additional evidence supporting the quality and durability of knee cartilage regenerated with GelrinC, as the company advances its U.S. pivotal trial and commercialization efforts in Europe.
Cartilage repair is intended to do more than simply reduce pain. Ideally, proper treatment should also restore the cartilage tissue responsible for the smooth movement and durability of a healthy joint.
That can be difficult to achieve.
One challenge is that some commonly used cartilage-repair procedures encourage the formation of fibrocartilage rather than native hyaline cartilage. Fibrocartilage can fill structural defects and provide pain relief, but it does not have the same properties as hyaline cartilage, the smooth, resilient tissue that normally covers the surfaces of joints.
That distinction becomes particularly important over time. A treatment that provides short-term pain relief does not necessarily address the underlying loss of durable cartilage, potentially leaving younger and active patients facing additional procedures as joint damage progresses.
Regentis Biomaterials Ltd. (NYSE American: RGNT) is developing a regenerative approach designed to address that challenge with GelrinC, its lead product for the treatment of painful focal articular knee cartilage injuries.
The company’s lead product, GelrinC, is a cell-free, off-the-shelf hydrogel that is introduced directly into a cartilage lesion. Rather than permanently replacing the damaged tissue, the implant is designed to temporarily fill the defect while creating an environment that supports surrounding cells to regenerate new cartilage as GelrinC itself is resorbed.
GelrinC is introduced into the cartilage lesion using a syringe. Once the defect is filled, a UV beam cures the material into a soft, rubbery implant that temporarily occupies the damaged area.
From there, the process shifts from implantation to regeneration.
As the GelrinC implant gradually resorbs, the surrounding cartilage lesion rim forms aggregates and new cartilage begins to advance from the rims toward the center filling the space left by the retreating GelrinC implant. In time, the implant is completely resorbed, and new healthy cartilage covers the treated lesion.
According to the company’s clinical data, the regenerated cartilage is like healthy, native hyaline cartilage of the patient’s own. More recent imaging data provide additional insight into how that regenerated tissue develops over time.
In a clinical study followed to 24 months, GelrinC-treated patients demonstrated layered cartilage architecture comparable to native hyaline cartilage, according to long-term MRI data reported by Regentis. The company said the analysis used validated MRI methodologies accepted by U.S. and European regulators and showed progressive maturation and organization of the regenerated cartilage over time.
The findings complement previously reported clinical results from the company’s Phase II, which treated 56 patients across multiple sites in Israel and Northern Europe and followed patients for up to five years.
According to Regentis, patients treated with GelrinC demonstrated greater improvement in pain measurements compared with traditional microfracture. No serious adverse events were observed in the completed study.
GelrinC was also reviewed in peer-reviewed articles of the Cartilage journal using quantitative MOCART assessment of the complete Phase II follow-up dataset. The analysis demonstrated durable morphological cartilage repair through the standard two years follow-up and provided additional support for the quality and durability of the regenerated tissue.
Together, these findings are particularly relevant to the central challenge facing cartilage repair: not simply filling a defect but producing tissue that can mature and potentially provide lasting joint function.
That objective is now being evaluated in a larger U.S. clinical program.
Regentis has treated 43 of the 80 planned patients in its U.S. pivotal Phase III trial and expects to complete enrollment around the end of 2026. The company has also expanded its U.S. clinical site network while adding sites across Europe as it builds a broader clinical network.
At the same time, Regentis is preparing for potential commercialization in Europe, where GelrinC already has CE Mark approval. The company is engaging physicians and clinical centers and expanding surgeon training through its European Centers of Excellence.
Manufacturing is another part of that commercialization effort.
Regentis recently developed and filed patents covering a new solvent-free manufacturing process that the company says increases GelrinC production yield by 400%. In July 2026, the company received regulatory approval for the new manufacturing process from the European Notified Body, supporting manufacturing scale-up for anticipated European commercial requirements and future market expansion.
The combination of clinical development, manufacturing improvements and commercialization preparation gives GelrinC a broader development story than simply another approach to treating knee pain.
The underlying question is whether damaged cartilage can be repaired in a way that provides more than temporary relief, by encouraging the regeneration of tissue that more closely resembles the structure and characteristics of native cartilage. Regentis is now advancing GelrinC toward that goal through its U.S. pivotal trial while simultaneously preparing its European infrastructure for potential commercialization.
If successful, the approach could provide physicians with a cell-free, off-the-shelf product option designed to regenerate cartilage rather than simply manage the symptoms associated with its loss.
NOTE TO INVESTORS: The latest news and updates relating to RGNT are available in the company’s newsroom at ibn.fm/RGNT
This content was disseminated on behalf of (NYSE American: RGNT) as part of a paid marketing engagement with IBN.Ai
RGNT: IBN will receive $30,000 per quarter for a total of 180 days from RGNT for coverage via IBN
Please see full terms of use and disclaimers on the IBN website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer
About MissionIR
MissionIR (“MIR”) is a specialized communications platform with a focus on assisting IR firms with syndicated content to enhance the visibility of private and public companies within the investment community. It is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, MIR is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, MIR brings its clients unparalleled recognition and brand awareness.
MIR is where breaking news, insightful content and actionable information converge.
For more information, please visit www.MissionIR.com
Please see full terms of use and disclaimers on the MissionIR website applicable to all content provided by MIR, wherever published or re-published: https://www.MissionIR.com/Disclaimer
MissionIR
Austin, Texas
www.MissionIR.com
512.354.7000 Office
Editor@MissionIR.com
MissionIR is powered by IBN